nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—SLC15A2—melanoma	0.312	0.56	CbGaD
Nateglinide—PPARG—melanoma	0.178	0.32	CbGaD
Nateglinide—ORM1—Vemurafenib—melanoma	0.126	0.405	CbGbCtD
Nateglinide—ALB—melanoma	0.0671	0.12	CbGaD
Nateglinide—ALB—Vemurafenib—melanoma	0.053	0.17	CbGbCtD
Nateglinide—CYP3A4—Temozolomide—melanoma	0.0303	0.0974	CbGbCtD
Nateglinide—CYP2D6—Vemurafenib—melanoma	0.0261	0.0839	CbGbCtD
Nateglinide—CYP3A7—Docetaxel—melanoma	0.0195	0.0626	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.0195	0.0626	CbGbCtD
Nateglinide—CYP3A4—Vemurafenib—melanoma	0.0166	0.0534	CbGbCtD
Nateglinide—CYP3A5—Docetaxel—melanoma	0.0146	0.047	CbGbCtD
Nateglinide—CYP3A4—Docetaxel—melanoma	0.0057	0.0183	CbGbCtD
Nateglinide—PPARG—dermis—melanoma	0.00331	0.167	CbGeAlD
Nateglinide—PPARG—leg—melanoma	0.00219	0.111	CbGeAlD
Nateglinide—PPARG—hindlimb—melanoma	0.00195	0.0987	CbGeAlD
Nateglinide—PPARG—appendage—melanoma	0.00168	0.0847	CbGeAlD
Nateglinide—Trauma—Bleomycin—melanoma	0.00153	0.0565	CcSEcCtD
Nateglinide—PPARG—endothelium—melanoma	0.00101	0.0511	CbGeAlD
Nateglinide—PPARG—blood vessel—melanoma	0.000933	0.0471	CbGeAlD
Nateglinide—Spirapril—SLC15A2—melanoma	0.000819	0.195	CrCbGaD
Nateglinide—Cilazapril—SLC15A2—melanoma	0.00073	0.174	CrCbGaD
Nateglinide—Ramipril—SLC15A2—melanoma	0.000707	0.169	CrCbGaD
Nateglinide—Trandolapril—SLC15A2—melanoma	0.000707	0.169	CrCbGaD
Nateglinide—PPARG—neck—melanoma	0.000667	0.0337	CbGeAlD
Nateglinide—Neuropathy peripheral—Vemurafenib—melanoma	0.000661	0.0243	CcSEcCtD
Nateglinide—Hepatic enzyme increased—Temozolomide—melanoma	0.000651	0.024	CcSEcCtD
Nateglinide—Oedema peripheral—Vemurafenib—melanoma	0.000596	0.022	CcSEcCtD
Nateglinide—SLC16A1—eye—melanoma	0.000592	0.0299	CbGeAlD
Nateglinide—SLC16A1—retina—melanoma	0.000586	0.0296	CbGeAlD
Nateglinide—Injury—Bleomycin—melanoma	0.000577	0.0212	CcSEcCtD
Nateglinide—Erythema multiforme—Vemurafenib—melanoma	0.000572	0.0211	CcSEcCtD
Nateglinide—PTGS1—endothelium—melanoma	0.000541	0.0273	CbGeAlD
Nateglinide—Malnutrition—Vemurafenib—melanoma	0.000527	0.0194	CcSEcCtD
Nateglinide—Back pain—Vemurafenib—melanoma	0.00051	0.0188	CcSEcCtD
Nateglinide—Injury—Carmustine—melanoma	0.000503	0.0185	CcSEcCtD
Nateglinide—PTGS1—blood vessel—melanoma	0.000499	0.0252	CbGeAlD
Nateglinide—SLC15A1—mammalian vulva—melanoma	0.000493	0.0249	CbGeAlD
Nateglinide—Thirst—Temozolomide—melanoma	0.00047	0.0173	CcSEcCtD
Nateglinide—Cough—Vemurafenib—melanoma	0.00046	0.0169	CcSEcCtD
Nateglinide—PPARG—skin of body—melanoma	0.000432	0.0218	CbGeAlD
Nateglinide—Mitiglinide—PPARG—melanoma	0.000411	0.0981	CrCbGaD
Nateglinide—Lacosamide—SCN10A—melanoma	0.000407	0.097	CrCbGaD
Nateglinide—KCNJ11—head—melanoma	0.000401	0.0202	CbGeAlD
Nateglinide—PPARG—mammalian vulva—melanoma	0.000394	0.0199	CbGeAlD
Nateglinide—SLC15A2—retina—melanoma	0.000385	0.0195	CbGeAlD
Nateglinide—Sweating increased—Temozolomide—melanoma	0.000376	0.0139	CcSEcCtD
Nateglinide—Bronchitis—Temozolomide—melanoma	0.000372	0.0137	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Vemurafenib—melanoma	0.000371	0.0137	CcSEcCtD
Nateglinide—Fatigue—Vemurafenib—melanoma	0.000371	0.0137	CcSEcCtD
Nateglinide—ABCC8—head—melanoma	0.000369	0.0187	CbGeAlD
Nateglinide—Upper respiratory tract infection—Temozolomide—melanoma	0.000359	0.0132	CcSEcCtD
Nateglinide—Neuropathy peripheral—Carmustine—melanoma	0.00035	0.0129	CcSEcCtD
Nateglinide—Neuropathy peripheral—Temozolomide—melanoma	0.000338	0.0124	CcSEcCtD
Nateglinide—SLC16A1—head—melanoma	0.000336	0.017	CbGeAlD
Nateglinide—Hepatobiliary disease—Temozolomide—melanoma	0.000326	0.012	CcSEcCtD
Nateglinide—Erythema multiforme—Dactinomycin—melanoma	0.000323	0.0119	CcSEcCtD
Nateglinide—Hypersensitivity—Vemurafenib—melanoma	0.000317	0.0117	CcSEcCtD
Nateglinide—Oedema peripheral—Carmustine—melanoma	0.000315	0.0116	CcSEcCtD
Nateglinide—Asthenia—Vemurafenib—melanoma	0.000309	0.0114	CcSEcCtD
Nateglinide—Oedema peripheral—Temozolomide—melanoma	0.000305	0.0112	CcSEcCtD
Nateglinide—Pruritus—Vemurafenib—melanoma	0.000304	0.0112	CcSEcCtD
Nateglinide—Diarrhoea—Vemurafenib—melanoma	0.000294	0.0108	CcSEcCtD
Nateglinide—Erythema multiforme—Temozolomide—melanoma	0.000292	0.0108	CcSEcCtD
Nateglinide—Dizziness—Vemurafenib—melanoma	0.000284	0.0105	CcSEcCtD
Nateglinide—PPARG—head—melanoma	0.000282	0.0142	CbGeAlD
Nateglinide—KCNJ11—lymph node—melanoma	0.000281	0.0142	CbGeAlD
Nateglinide—Immune system disorder—Temozolomide—melanoma	0.000279	0.0103	CcSEcCtD
Nateglinide—Malnutrition—Carmustine—melanoma	0.000279	0.0103	CcSEcCtD
Nateglinide—Cough—Bleomycin—melanoma	0.000279	0.0103	CcSEcCtD
Nateglinide—Vomiting—Vemurafenib—melanoma	0.000273	0.0101	CcSEcCtD
Nateglinide—Rash—Vemurafenib—melanoma	0.000271	0.00999	CcSEcCtD
Nateglinide—Dermatitis—Vemurafenib—melanoma	0.000271	0.00998	CcSEcCtD
Nateglinide—Back pain—Carmustine—melanoma	0.00027	0.00993	CcSEcCtD
Nateglinide—Malnutrition—Temozolomide—melanoma	0.000269	0.00992	CcSEcCtD
Nateglinide—Tremor—Carmustine—melanoma	0.000261	0.00961	CcSEcCtD
Nateglinide—Back pain—Temozolomide—melanoma	0.00026	0.00959	CcSEcCtD
Nateglinide—ABCC4—head—melanoma	0.000256	0.0129	CbGeAlD
Nateglinide—Nausea—Vemurafenib—melanoma	0.000255	0.00941	CcSEcCtD
Nateglinide—Tremor—Temozolomide—melanoma	0.000252	0.00929	CcSEcCtD
Nateglinide—Palpitations—Temozolomide—melanoma	0.000238	0.00876	CcSEcCtD
Nateglinide—SLC16A1—lymph node—melanoma	0.000235	0.0119	CbGeAlD
Nateglinide—Cough—Temozolomide—melanoma	0.000235	0.00865	CcSEcCtD
Nateglinide—PTGS1—skin of body—melanoma	0.000231	0.0117	CbGeAlD
Nateglinide—Neuropathy peripheral—Docetaxel—melanoma	0.000225	0.00827	CcSEcCtD
Nateglinide—Jaundice—Docetaxel—melanoma	0.000223	0.00823	CcSEcCtD
Nateglinide—SLC15A2—head—melanoma	0.000221	0.0111	CbGeAlD
Nateglinide—Hepatobiliary disease—Docetaxel—melanoma	0.000217	0.00798	CcSEcCtD
Nateglinide—Hyperhidrosis—Temozolomide—melanoma	0.000212	0.00782	CcSEcCtD
Nateglinide—ORM1—lymph node—melanoma	0.000211	0.0107	CbGeAlD
Nateglinide—PTGS1—mammalian vulva—melanoma	0.000211	0.0106	CbGeAlD
Nateglinide—Fatigue—Dactinomycin—melanoma	0.000209	0.00771	CcSEcCtD
Nateglinide—Urticaria—Bleomycin—melanoma	0.000207	0.00762	CcSEcCtD
Nateglinide—Oedema peripheral—Docetaxel—melanoma	0.000203	0.00746	CcSEcCtD
Nateglinide—Gastrointestinal pain—Dactinomycin—melanoma	0.000199	0.00732	CcSEcCtD
Nateglinide—PPARG—lymph node—melanoma	0.000197	0.00997	CbGeAlD
Nateglinide—Gastrointestinal disorder—Carmustine—melanoma	0.000196	0.00723	CcSEcCtD
Nateglinide—Erythema multiforme—Docetaxel—melanoma	0.000195	0.00716	CcSEcCtD
Nateglinide—Dyspepsia—Temozolomide—melanoma	0.000193	0.00712	CcSEcCtD
Nateglinide—Abdominal pain—Dactinomycin—melanoma	0.000192	0.00707	CcSEcCtD
Nateglinide—Hypersensitivity—Bleomycin—melanoma	0.000192	0.00707	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Temozolomide—melanoma	0.00019	0.00699	CcSEcCtD
Nateglinide—Fatigue—Temozolomide—melanoma	0.000189	0.00698	CcSEcCtD
Nateglinide—Asthenia—Bleomycin—melanoma	0.000187	0.00688	CcSEcCtD
Nateglinide—Gastrointestinal pain—Carmustine—melanoma	0.000186	0.00685	CcSEcCtD
Nateglinide—Immune system disorder—Docetaxel—melanoma	0.000186	0.00684	CcSEcCtD
Nateglinide—ALB—lymph node—melanoma	0.000185	0.00935	CbGeAlD
Nateglinide—Pruritus—Bleomycin—melanoma	0.000184	0.00679	CcSEcCtD
Nateglinide—Abdominal pain—Carmustine—melanoma	0.00018	0.00662	CcSEcCtD
Nateglinide—Gastrointestinal pain—Temozolomide—melanoma	0.00018	0.00662	CcSEcCtD
Nateglinide—ABCC4—lymph node—melanoma	0.000179	0.00905	CbGeAlD
Nateglinide—Malnutrition—Docetaxel—melanoma	0.000179	0.00659	CcSEcCtD
Nateglinide—Hypersensitivity—Dactinomycin—melanoma	0.000179	0.00659	CcSEcCtD
Nateglinide—Urticaria—Temozolomide—melanoma	0.000175	0.00643	CcSEcCtD
Nateglinide—Asthenia—Dactinomycin—melanoma	0.000174	0.00642	CcSEcCtD
Nateglinide—Abdominal pain—Temozolomide—melanoma	0.000174	0.0064	CcSEcCtD
Nateglinide—Back pain—Docetaxel—melanoma	0.000173	0.00638	CcSEcCtD
Nateglinide—Hypersensitivity—Carmustine—melanoma	0.000168	0.00617	CcSEcCtD
Nateglinide—Diarrhoea—Dactinomycin—melanoma	0.000166	0.00612	CcSEcCtD
Nateglinide—Vomiting—Bleomycin—melanoma	0.000166	0.0061	CcSEcCtD
Nateglinide—Rash—Bleomycin—melanoma	0.000164	0.00605	CcSEcCtD
Nateglinide—Dermatitis—Bleomycin—melanoma	0.000164	0.00604	CcSEcCtD
Nateglinide—Asthenia—Carmustine—melanoma	0.000163	0.00601	CcSEcCtD
Nateglinide—Hypersensitivity—Temozolomide—melanoma	0.000162	0.00596	CcSEcCtD
Nateglinide—Palpitations—Docetaxel—melanoma	0.000158	0.00583	CcSEcCtD
Nateglinide—Asthenia—Temozolomide—melanoma	0.000158	0.00581	CcSEcCtD
Nateglinide—Cough—Docetaxel—melanoma	0.000156	0.00575	CcSEcCtD
Nateglinide—Diarrhoea—Carmustine—melanoma	0.000156	0.00573	CcSEcCtD
Nateglinide—Pruritus—Temozolomide—melanoma	0.000155	0.00573	CcSEcCtD
Nateglinide—Nausea—Bleomycin—melanoma	0.000155	0.0057	CcSEcCtD
Nateglinide—SLC15A2—lymph node—melanoma	0.000155	0.00781	CbGeAlD
Nateglinide—Vomiting—Dactinomycin—melanoma	0.000154	0.00569	CcSEcCtD
Nateglinide—Rash—Dactinomycin—melanoma	0.000153	0.00564	CcSEcCtD
Nateglinide—PTGS1—head—melanoma	0.000151	0.00761	CbGeAlD
Nateglinide—Dizziness—Carmustine—melanoma	0.00015	0.00554	CcSEcCtD
Nateglinide—Diarrhoea—Temozolomide—melanoma	0.00015	0.00554	CcSEcCtD
Nateglinide—Cilazapril—ABCB1—melanoma	0.00015	0.0358	CrCbGaD
Nateglinide—Lisinopril—ABCB1—melanoma	0.00015	0.0358	CrCbGaD
Nateglinide—Dizziness—Temozolomide—melanoma	0.000145	0.00535	CcSEcCtD
Nateglinide—Vomiting—Carmustine—melanoma	0.000145	0.00533	CcSEcCtD
Nateglinide—Nausea—Dactinomycin—melanoma	0.000144	0.00532	CcSEcCtD
Nateglinide—Rash—Carmustine—melanoma	0.000143	0.00528	CcSEcCtD
Nateglinide—Dermatitis—Carmustine—melanoma	0.000143	0.00528	CcSEcCtD
Nateglinide—Vomiting—Temozolomide—melanoma	0.00014	0.00515	CcSEcCtD
Nateglinide—Rash—Temozolomide—melanoma	0.000139	0.0051	CcSEcCtD
Nateglinide—Dermatitis—Temozolomide—melanoma	0.000138	0.0051	CcSEcCtD
Nateglinide—Nausea—Carmustine—melanoma	0.000135	0.00497	CcSEcCtD
Nateglinide—Nausea—Temozolomide—melanoma	0.000131	0.00481	CcSEcCtD
Nateglinide—Dyspepsia—Docetaxel—melanoma	0.000129	0.00474	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Docetaxel—melanoma	0.000126	0.00465	CcSEcCtD
Nateglinide—Fatigue—Docetaxel—melanoma	0.000126	0.00464	CcSEcCtD
Nateglinide—CYP2D6—head—melanoma	0.000124	0.00626	CbGeAlD
Nateglinide—Gastrointestinal pain—Docetaxel—melanoma	0.00012	0.0044	CcSEcCtD
Nateglinide—Abdominal pain—Docetaxel—melanoma	0.000116	0.00425	CcSEcCtD
Nateglinide—Enalapril—ABCB1—melanoma	0.00011	0.0263	CrCbGaD
Nateglinide—Hypersensitivity—Docetaxel—melanoma	0.000108	0.00397	CcSEcCtD
Nateglinide—PTGS1—lymph node—melanoma	0.000106	0.00533	CbGeAlD
Nateglinide—Asthenia—Docetaxel—melanoma	0.000105	0.00386	CcSEcCtD
Nateglinide—Pruritus—Docetaxel—melanoma	0.000103	0.00381	CcSEcCtD
Nateglinide—Diarrhoea—Docetaxel—melanoma	0.0001	0.00368	CcSEcCtD
Nateglinide—Dizziness—Docetaxel—melanoma	9.66e-05	0.00356	CcSEcCtD
Nateglinide—Vomiting—Docetaxel—melanoma	9.29e-05	0.00342	CcSEcCtD
Nateglinide—Rash—Docetaxel—melanoma	9.22e-05	0.00339	CcSEcCtD
Nateglinide—Dermatitis—Docetaxel—melanoma	9.21e-05	0.00339	CcSEcCtD
Nateglinide—Nausea—Docetaxel—melanoma	8.68e-05	0.0032	CcSEcCtD
Nateglinide—SLC16A1—Hemostasis—AKT1—melanoma	8.43e-06	0.000105	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—CDK2—melanoma	8.38e-06	0.000104	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—KRAS—melanoma	8.38e-06	0.000104	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—HPSE—melanoma	8.37e-06	0.000104	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—VCAN—melanoma	8.33e-06	0.000103	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CUBN—melanoma	8.29e-06	0.000103	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CD44—melanoma	8.27e-06	0.000103	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—GNAQ—melanoma	8.27e-06	0.000103	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PIK3CD—melanoma	8.24e-06	0.000102	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CUBN—melanoma	8.22e-06	0.000102	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—MAPK3—melanoma	8.18e-06	0.000102	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—CYP1B1—melanoma	8.18e-06	0.000102	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—ALB—melanoma	8.14e-06	0.000101	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	8.1e-06	0.000101	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—melanoma	8.02e-06	9.97e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—ABCB1—melanoma	8.01e-06	9.95e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CSPG4—melanoma	8e-06	9.94e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SDHD—melanoma	8e-06	9.94e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—BSG—melanoma	8e-06	9.94e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PIK3CD—melanoma	7.99e-06	9.93e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PLA2G6—melanoma	7.98e-06	9.91e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CSPG4—melanoma	7.94e-06	9.85e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SDHD—melanoma	7.94e-06	9.85e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—BSG—melanoma	7.94e-06	9.85e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CYP1B1—melanoma	7.93e-06	9.85e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—ALB—melanoma	7.89e-06	9.8e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PIK3CD—melanoma	7.88e-06	9.78e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—FN1—melanoma	7.79e-06	9.68e-05	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—MAPK1—melanoma	7.79e-06	9.67e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—ALB—melanoma	7.78e-06	9.66e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GPAM—melanoma	7.75e-06	9.63e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—NOS2—melanoma	7.7e-06	9.56e-05	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—PIK3CA—melanoma	7.7e-06	9.56e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GPAM—melanoma	7.69e-06	9.54e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PIK3CG—melanoma	7.46e-06	9.26e-05	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—TP53—melanoma	7.45e-06	9.25e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PRKCA—melanoma	7.37e-06	9.15e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—EGF—melanoma	7.37e-06	9.15e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—ERCC2—melanoma	7.31e-06	9.08e-05	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—HRAS—melanoma	7.3e-06	9.07e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PIK3CB—melanoma	7.18e-06	8.92e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—VCAN—melanoma	7.17e-06	8.91e-05	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—HRAS—melanoma	7.12e-06	8.84e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PTGS2—melanoma	7.12e-06	8.84e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	7.05e-06	8.75e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CYP17A1—melanoma	7.03e-06	8.72e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—melanoma	7e-06	8.69e-05	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—IL6—melanoma	6.99e-06	8.68e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PIK3CB—melanoma	6.97e-06	8.65e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PLCB4—melanoma	6.91e-06	8.58e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PTGS2—melanoma	6.9e-06	8.57e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PIK3CB—melanoma	6.87e-06	8.53e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—IGF1—melanoma	6.83e-06	8.48e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PTGS2—melanoma	6.8e-06	8.45e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	6.79e-06	8.43e-05	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—PIK3CA—melanoma	6.76e-06	8.39e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—ABCB1—melanoma	6.74e-06	8.37e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3CG—melanoma	6.72e-06	8.34e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GNA11—melanoma	6.63e-06	8.24e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PLA2G6—melanoma	6.59e-06	8.19e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PIK3CD—melanoma	6.55e-06	8.14e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PPARG—melanoma	6.55e-06	8.14e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PLA2G6—melanoma	6.53e-06	8.12e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—ABCB1—melanoma	6.53e-06	8.11e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC6A11—melanoma	6.49e-06	8.06e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIP4K2A—melanoma	6.49e-06	8.06e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—FASN—melanoma	6.49e-06	8.06e-05	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—AKT1—melanoma	6.45e-06	8.01e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—SLC5A5—melanoma	6.39e-06	7.93e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—MTAP—melanoma	6.32e-06	7.84e-05	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—AKT1—melanoma	6.29e-06	7.81e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PTEN—melanoma	6.21e-06	7.71e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PRKCA—melanoma	6.2e-06	7.7e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GNAQ—melanoma	6.17e-06	7.66e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CD44—melanoma	6.17e-06	7.66e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—ERCC2—melanoma	6.15e-06	7.64e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.06e-06	7.52e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP17A1—melanoma	6.05e-06	7.51e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PTEN—melanoma	6.02e-06	7.48e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PRKCA—melanoma	6.01e-06	7.46e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	5.97e-06	7.41e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—ERCC2—melanoma	5.96e-06	7.4e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PTEN—melanoma	5.93e-06	7.37e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—VCAN—melanoma	5.92e-06	7.35e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CYP1B1—melanoma	5.91e-06	7.34e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3CD—melanoma	5.91e-06	7.34e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—VCAN—melanoma	5.87e-06	7.29e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—ALB—melanoma	5.83e-06	7.24e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CG—melanoma	5.77e-06	7.17e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GNA11—melanoma	5.71e-06	7.1e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PIK3CB—melanoma	5.71e-06	7.1e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—LUM—melanoma	5.63e-06	6.99e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PHGDH—melanoma	5.63e-06	6.99e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—FASN—melanoma	5.59e-06	6.94e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PPARG—melanoma	5.57e-06	6.92e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	5.56e-06	6.9e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HPSE—melanoma	5.52e-06	6.86e-05	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—AKT1—melanoma	5.52e-06	6.85e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—SLC5A5—melanoma	5.5e-06	6.83e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CUBN—melanoma	5.42e-06	6.73e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	5.36e-06	6.66e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GNAQ—melanoma	5.31e-06	6.6e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CD44—melanoma	5.31e-06	6.6e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—IL2—melanoma	5.25e-06	6.52e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—BSG—melanoma	5.23e-06	6.5e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CSPG4—melanoma	5.23e-06	6.5e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SDHD—melanoma	5.23e-06	6.5e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	5.2e-06	6.46e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	5.15e-06	6.4e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3CB—melanoma	5.15e-06	6.39e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PTGS2—melanoma	5.1e-06	6.34e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP1B1—melanoma	5.09e-06	6.32e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CD—melanoma	5.08e-06	6.3e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GPAM—melanoma	5.07e-06	6.29e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—ALB—melanoma	5.01e-06	6.22e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP17A1—melanoma	5e-06	6.2e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP17A1—melanoma	4.95e-06	6.15e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.94e-06	6.13e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—MAPK3—melanoma	4.89e-06	6.07e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.88e-06	6.07e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ABCB1—melanoma	4.87e-06	6.05e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CG—melanoma	4.86e-06	6.03e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	4.82e-06	5.99e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—MYC—melanoma	4.76e-06	5.9e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GNA11—melanoma	4.72e-06	5.86e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CG—melanoma	4.71e-06	5.85e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PPARG—melanoma	4.69e-06	5.82e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GNA11—melanoma	4.68e-06	5.81e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—FASN—melanoma	4.62e-06	5.73e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—FASN—melanoma	4.58e-06	5.68e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PPARG—melanoma	4.54e-06	5.64e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SLC5A5—melanoma	4.54e-06	5.64e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SLC5A5—melanoma	4.5e-06	5.59e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	4.49e-06	5.58e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PRKCA—melanoma	4.48e-06	5.57e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—VEGFA—melanoma	4.46e-06	5.54e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PTEN—melanoma	4.45e-06	5.53e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ERCC2—melanoma	4.44e-06	5.52e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CB—melanoma	4.42e-06	5.49e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—NRAS—melanoma	4.4e-06	5.47e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CD44—melanoma	4.39e-06	5.45e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GNAQ—melanoma	4.39e-06	5.45e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PTGS2—melanoma	4.38e-06	5.44e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PIK3CA—melanoma	4.38e-06	5.44e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GNAQ—melanoma	4.35e-06	5.4e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CD44—melanoma	4.35e-06	5.4e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PLA2G6—melanoma	4.31e-06	5.35e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CD—melanoma	4.27e-06	5.3e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	4.26e-06	5.29e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PIK3CA—melanoma	4.25e-06	5.27e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	4.22e-06	5.24e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—MAPK3—melanoma	4.22e-06	5.24e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—ALB—melanoma	4.21e-06	5.23e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP1B1—melanoma	4.2e-06	5.22e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ABCB1—melanoma	4.19e-06	5.21e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PIK3CA—melanoma	4.19e-06	5.2e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP1B1—melanoma	4.17e-06	5.18e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CD—melanoma	4.14e-06	5.14e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—ALB—melanoma	4.08e-06	5.07e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—MAPK1—melanoma	4.01e-06	4.98e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—VCAN—melanoma	3.87e-06	4.81e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PRKCA—melanoma	3.86e-06	4.79e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ERCC2—melanoma	3.83e-06	4.75e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PTEN—melanoma	3.82e-06	4.75e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—KRAS—melanoma	3.79e-06	4.71e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CB—melanoma	3.72e-06	4.62e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTGS2—melanoma	3.69e-06	4.58e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.68e-06	4.57e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CB—melanoma	3.61e-06	4.48e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—AKT1—melanoma	3.58e-06	4.44e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PTGS2—melanoma	3.57e-06	4.44e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CG—melanoma	3.51e-06	4.36e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PIK3CA—melanoma	3.48e-06	4.33e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—AKT1—melanoma	3.47e-06	4.31e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ABCB1—melanoma	3.46e-06	4.3e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ABCB1—melanoma	3.43e-06	4.26e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—AKT1—melanoma	3.42e-06	4.25e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PPARG—melanoma	3.39e-06	4.21e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—TP53—melanoma	3.37e-06	4.18e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—AKT1—melanoma	3.3e-06	4.09e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP17A1—melanoma	3.27e-06	4.06e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—HRAS—melanoma	3.22e-06	4e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTEN—melanoma	3.22e-06	3.99e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PRKCA—melanoma	3.19e-06	3.96e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.17e-06	3.94e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ERCC2—melanoma	3.16e-06	3.92e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PRKCA—melanoma	3.16e-06	3.92e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3CA—melanoma	3.14e-06	3.9e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ERCC2—melanoma	3.13e-06	3.89e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PTEN—melanoma	3.12e-06	3.87e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CD—melanoma	3.09e-06	3.83e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GNA11—melanoma	3.08e-06	3.83e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ALB—melanoma	3.05e-06	3.78e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CG—melanoma	3.02e-06	3.75e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—FASN—melanoma	3.02e-06	3.75e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC5A5—melanoma	2.97e-06	3.69e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PPARG—melanoma	2.92e-06	3.62e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GNAQ—melanoma	2.87e-06	3.56e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CD44—melanoma	2.87e-06	3.56e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—AKT1—melanoma	2.85e-06	3.53e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP1B1—melanoma	2.75e-06	3.41e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CA—melanoma	2.7e-06	3.35e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CB—melanoma	2.69e-06	3.34e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTGS2—melanoma	2.67e-06	3.31e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CD—melanoma	2.66e-06	3.3e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.6e-06	3.22e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—AKT1—melanoma	2.56e-06	3.18e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CG—melanoma	2.5e-06	3.1e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CG—melanoma	2.47e-06	3.07e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PPARG—melanoma	2.41e-06	2.99e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PPARG—melanoma	2.39e-06	2.97e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTEN—melanoma	2.32e-06	2.89e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CB—melanoma	2.32e-06	2.88e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTGS2—melanoma	2.3e-06	2.85e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CA—melanoma	2.27e-06	2.82e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ABCB1—melanoma	2.26e-06	2.81e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—AKT1—melanoma	2.2e-06	2.74e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CA—melanoma	2.2e-06	2.73e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CD—melanoma	2.19e-06	2.72e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CD—melanoma	2.18e-06	2.7e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ALB—melanoma	2.17e-06	2.69e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ALB—melanoma	2.15e-06	2.67e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PRKCA—melanoma	2.08e-06	2.59e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ERCC2—melanoma	2.07e-06	2.57e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTEN—melanoma	2e-06	2.49e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CB—melanoma	1.91e-06	2.38e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CB—melanoma	1.9e-06	2.35e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTGS2—melanoma	1.9e-06	2.35e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTGS2—melanoma	1.88e-06	2.33e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—AKT1—melanoma	1.85e-06	2.3e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—AKT1—melanoma	1.8e-06	2.23e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTEN—melanoma	1.65e-06	2.05e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CA—melanoma	1.64e-06	2.04e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTEN—melanoma	1.64e-06	2.03e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CG—melanoma	1.63e-06	2.03e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PPARG—melanoma	1.58e-06	1.96e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CD—melanoma	1.43e-06	1.78e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ALB—melanoma	1.42e-06	1.76e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CA—melanoma	1.41e-06	1.75e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—AKT1—melanoma	1.34e-06	1.66e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CB—melanoma	1.25e-06	1.55e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTGS2—melanoma	1.24e-06	1.54e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CA—melanoma	1.17e-06	1.45e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CA—melanoma	1.16e-06	1.44e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—AKT1—melanoma	1.15e-06	1.43e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTEN—melanoma	1.08e-06	1.34e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—AKT1—melanoma	9.52e-07	1.18e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—AKT1—melanoma	9.44e-07	1.17e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CA—melanoma	7.62e-07	9.47e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—AKT1—melanoma	6.23e-07	7.73e-06	CbGpPWpGaD
